Emerging risks | Growth Opportunities | APAC Insurance

Wednesday, January 14, 2026

Emerging risks | Growth opportunities | APAC insurance

Wednesday, 14 January 2026

Dedicated hubs

Browse content

Report: China Life invests US $42.4m in Series B round for Yingke Biopharmaceutic

Yingke was established in 2022 and is engaged in the R&D of pharmaceutical drugs
Report china life invests us 4m in series b round for yingke biopharmaceutic  rein asia

Stay ahead with precise, independent journalism of APAC's insurance markets.


Experience 7 days of full access to premium insights

Already a member?

Login here

Share this article

Read next